The Germany genomic biomarker market is estimated to grow significantly at a CAGR of 15.6% during the forecast period. It is due to the increasing geriatric population, the presence of highly specialized urologists for cancer treatment and bit low-cost treatment as compared to UK, which is attracting medical tourism in the country. In addition, Germany has a well-developed healthcare system and favorable government policies which are driving the market in the region.